An influencer-backed energy drink that has earned viral popularity among children is facing scrutiny from lawmakers and health experts over its potentially dangerous levels of caffeine
On Sunday, Sen. Charles Schumer called on the Food and Drug Administration to investigate PRIME, a beverage brand founded by the YouTube stars Logan Paul and KSI that has become something of an obsession among the influencers’ legions of young followers.
Backed by two of YouTube’s best known stars, PRIME was an immediate sensation when it launched last year, prompting long lines in grocery stores and reports of school yard resale markets. That high content prompted bans from some schools in the United Kingdom and Australia where some pediatricians warned of possible health impacts on young children such as heart problems, anxiety, and digestive issues.
But in his letter to the FDA, Schumer claimed there was little noticeable difference in the online marketing of the two drinks – leading many parents to believe they were purchasing a juice for their kids, only to wind up with a “cauldron of caffeine.”
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Logan Canyon to get cell service; officials hope it will improve public safetyPlans are now underway to get a cell tower in Logan Canyon. In all, about $21 million has been secured to make it happen.
続きを読む »
Logan Webb in search of consistency as Giants face RockiesRight-hander Logan Webb hopes to finish off the first half of the season differently than he started it when the San Francisco Giants hand him the ball for the finale of a three-game series against the visiting Colorado Rockies on Sunday afternoon.
続きを読む »
The first drug that slows Alzheimer's has finally received FDA approval | EngadgetJapanese drugmaker Eisai and US-based Biogen have received FDA approval for Leqembi, making it the first approved treatment available that can slow the progression of Alzheimer’s in patients..
続きを読む »
Alzheimer’s drug Leqembi granted full FDA approvalIt’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
続きを読む »
Alzheimer's-slowing drug Leqembi gains full FDA approvalIt's the first time that a drug meant to slow the disease’s progression, and not only target its symptoms, has been granted full regulatory approval.
続きを読む »
In a First, FDA Grants Full Approval to Anti-Amyloid Drug for Alzheimer'sThe FDA's decision will allow the drug known as Leqembi to be widely available and covered through Medicare.
続きを読む »